VGX 0111
Alternative Names: VGX-0111Latest Information Update: 11 Dec 2023
At a glance
- Originator Visgenx
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 07 Dec 2023 Visgenx plans a clinical proof of concept for Dry age-related macular degeneration in 2025
- 26 Oct 2023 Visgenx has patent protection for compositions of candidate entitled 'ELOVL2 Constructs for Human Gene Therapy' in USA
- 30 Jun 2023 Visgenx completes a Type B pre-IND meeting with US FDA